Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central anxious method, conolidine modulates alternate molecular targets. A Science Developments review located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://peterj465cqh5.atualblog.com/profile